<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="169283">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00893074</url>
  </required_header>
  <id_info>
    <org_study_id>NA_00026278</org_study_id>
    <secondary_id>R01DA025044</secondary_id>
    <nct_id>NCT00893074</nct_id>
  </id_info>
  <brief_title>The Effect of Prescription Medications in Marijuana Users</brief_title>
  <official_title>The Effect of Prescription Medications in Marijuana Users</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A subset of heavy marijuana users have trouble quitting marijuana use and the number of
      those seeking treatment for problems related to marijuana is increasing. The purpose of this
      research study is to investigate whether certain medications can reduce withdrawal effects
      associated with stopping marijuana use, if they can reduce the rewarding effects of smoked
      marijuana, and whether there are any cognitive performance deficits associated with the
      medications that produce such effects.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2009</start_date>
  <completion_date type="Anticipated">October 2011</completion_date>
  <primary_completion_date type="Anticipated">October 2011</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double Blind (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>marijuana withdrawal</measure>
    <time_frame>Every day during study participation</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>subjective effects of smoked marijuana</measure>
    <time_frame>Every 5-9 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>cognitive performance</measure>
    <time_frame>Every 5-9 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">21</enrollment>
  <condition>Marijuana Abuse</condition>
  <arm_group>
    <arm_group_label>Marijuana Use</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Period during which participants are free to self administer marijuana</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Marijuana Abstinence</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period during which marijuana use is prohibited and study medication is administered</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bupropion, diazepam, dronabinol, ramelteon (Investigational Drug)</intervention_name>
    <description>multiple doses of an investigational drug administered three times per day, double blind during brief periods of marijuana abstinence</description>
    <arm_group_label>Marijuana Abstinence</arm_group_label>
    <other_name>buproprion</other_name>
    <other_name>diazepam</other_name>
    <other_name>dronabinol</other_name>
    <other_name>ramelteon</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  current use of marijuana

          -  able to give informed consent

        Exclusion Criteria:

          -  dependence on drug other than marijuana

          -  pregnant, breast feeding, or planning to become pregnant within the next 3 months

          -  currently seeking treatment for cannabis-related problems or otherwise trying to
             reduce use

          -  use of cannabis under the guidance of a physician for a medical disorder

          -  unstable or uncontrolled cardiovascular disease (e.g., hypertension, angina)

          -  allergy to study medication
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ryan Vandrey, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sarah Ilk</last_name>
    <phone>410-550-0007</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Behavioral Pharmacology Research Unit</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Ilk</last_name>
      <phone>410-550-0007</phone>
    </contact>
    <investigator>
      <last_name>Ryan Vandrey, Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2009</verification_date>
  <lastchanged_date>July 15, 2011</lastchanged_date>
  <firstreceived_date>April 30, 2009</firstreceived_date>
  <responsible_party>
    <name_title>Ryan Vandrey, Ph.D.</name_title>
    <organization>Johns Hopkins University School of Medicine</organization>
  </responsible_party>
  <keyword>withdrawal</keyword>
  <keyword>acute effects</keyword>
  <keyword>cognitive performance</keyword>
  <keyword>Marijuana Use</keyword>
  <keyword>Marijuana Abstinence</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Marijuana Abuse</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dronabinol</mesh_term>
    <mesh_term>Bupropion</mesh_term>
    <mesh_term>Diazepam</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
